Advances in Claudin18.2 Targeted Therapies for Gastroesophageal Cancers

Claudin18.2 (CLDN18.2) has emerged as a critical therapeutic target in the treatment of advanced gastric and gastroesophageal junction (GEJ) cancers. According to the U.S. Food and Drug Administration (FDA), the monoclonal antibody zolbetuximab represents the first targeted therapy approved for patients whose tumors express the CLDN18.2 protein. This treatment, when combined with chemotherapy, is indicated for adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.

Understanding the Role of Claudin18.2

Claudin18.2 is a tight-junction protein typically found in gastric mucosa. In certain gastroesophageal cancers, this protein becomes exposed on the cell surface due to the disruption of cell polarity, making it an accessible target for precision medicine. Because healthy tissues—outside of the stomach lining—generally do not express this protein, it serves as a highly specific marker for therapeutic intervention.

The development of therapies targeting this protein focuses on activating the immune system to destroy cancer cells. Zolbetuximab binds to CLDN18.2 on the surface of tumor cells, triggering antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which effectively leads to the death of the malignant cells.

Clinical Evidence and FDA Approval

The regulatory approval of zolbetuximab was primarily based on the results from the SPOTLIGHT and GLOW clinical trials. These phase 3 studies evaluated the efficacy of adding zolbetuximab to standard chemotherapy regimens compared to chemotherapy alone.

• SPOTLIGHT Trial: Patients receiving zolbetuximab plus mFOLFOX6 chemotherapy demonstrated a median progression-free survival (PFS) of 10.6 months, compared to 8.7 months in the placebo group.
• GLOW Trial: Patients treated with zolbetuximab plus CAPOX chemotherapy showed a median PFS of 8.2 months, compared to 6.8 months for those receiving chemotherapy and a placebo.

These findings indicate that incorporating CLDN18.2-targeted agents into first-line treatment protocols can extend the time patients live without their disease worsening.

Diagnostic Requirements for Targeted Treatment

Before initiating therapy with a CLDN18.2-targeted agent, clinicians must confirm the presence of the target protein in the patient’s tumor. The FDA approved a companion diagnostic, the VENTANA CLDN18 (43-14A) RxDx Assay, to identify patients who are candidates for this specific treatment. This test ensures that only individuals with a sufficient level of CLDN18.2 expression receive the therapy, optimizing the potential for clinical benefit and avoiding unnecessary side effects in patients whose tumors do not express the protein.

Considerations for Patient Management

While targeted therapies offer significant advantages, they are associated with specific toxicities. Common adverse reactions observed in clinical trials include nausea, vomiting, decreased appetite, and fatigue. According to clinical guidance, managing these symptoms is an essential component of the treatment plan, often requiring antiemetic prophylaxis and dose adjustments if severe gastrointestinal side effects occur.

Ongoing research continues to investigate the evolution of these therapies, including the potential for combining CLDN18.2 inhibitors with immune checkpoint inhibitors or other novel agents to further improve survival outcomes in patients with advanced gastric and GEJ malignancies.